Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 May;25(5):1110-5.
doi: 10.1007/s11095-007-9482-2. Epub 2008 Jan 3.

The USP Performance Verification Test, Part II: collaborative study of USP's Lot P Prednisone Tablets

Affiliations

The USP Performance Verification Test, Part II: collaborative study of USP's Lot P Prednisone Tablets

Maria Glasgow et al. Pharm Res. 2008 May.

Abstract

Purpose: Periodic performance verification testing (PVT) is used by laboratories to assess and demonstrate proficiency and for other purposes as well. For dissolution, the PVT is specified in the US Pharmacopeia General Chapter Dissolution <711> under the title Apparatus Suitability Test. For Apparatus 1 and 2, USP provides two reference standard tablets for this purpose. For each new lot of these reference standards, USP conducts a collaborative study.

Methods: For new USP Lot P Prednisone Tablets, 28 collaborating laboratories provided data. The study was conducted with three sets of tablets: Lot O open label, Lot O blinded, and Lot P blinded. The blinded Lot O data were used for apparatus suitability testing.

Results: Acceptance limits were determined after dropping data due to failure of apparatus suitability, identification of data as unusual on control charts, or protocol violations.

Conclusions: Results yielded acceptance criteria of (47, 82) for Apparatus 1 and (37, 70) for Apparatus 2. Results generally were similar for Lot P compared to results from Lot O except that the average percent dissolved for Lot P is greater than for Lot O with Apparatus 2.

PubMed Disclaimer

References

    1. Pharm Res. 2007 Nov;24(11):2018-24 - PubMed
    1. Pharm Res. 2008 May;25(5):1100-9 - PubMed

LinkOut - more resources